MIDASOLVE
"MIDASOLVE" is a word mark owned by Midatech Limited, filed at the CIPO on May 28, 2019. It is registered and covers classes 1, 5, 40 and 42.
- Status
- Registered
- Since October 9, 2024
- Filed
- May 28, 2019
- Registered
- October 9, 2024
- Expires
- October 9, 2034
- Application no.
- 1965262
- Registration no.
- TMA1262131
- Office
- CIPO
- Canadian Intellectual Property Office
- Mark type
- Word mark
- 4 classes
Who owns MIDASOLVE
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Midatech Limited
United Kingdom
Representative
Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
What the mark covers
The products and services MIDASOLVE is filed for, grouped by Nice class.
Nano-particles ingredients for use in the manufacture of pharmaceuticals, medicines and cosmetics; nano-particles for use as carriers for pharmaceuticals, medicines and cosmetics; macrocylic compounds, compositions and derivates used as solubilising and stabilising agents for use in manufacturing pharmaceuticals, medicines and cosmetics
Pharmaceuticals and medicines containing nano-particles for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, and central nervous system related diseases and disorders, viral diseases and disorders, namely common cold, influenza, rabies, measles, diarrhea, hepatitis, yellow fever, polio, smallpox, AIDS, oncoviruses, and spongiform encephalopathies, metabolic diseases and disorders, namely diabetes, hypoglycemia, anemia, bulimia nervosa, anorexia, obesity, gout, osteoarthritis, and muscular dystrophy, endocrine diseases and disorders, namely growth and thyroid disorders, diabetes, osteoporosis, Addison's disease, Cushing's syndrome, Grave's disease, hyperglycemia, hypoglycemia, low testosterone, menopause, and obesity, genitourinary diseases and disorders, namely urological diseases, infertility, sexually transmitted diseases, and inflammatory pelvic diseases, neurological diseases and disorders, namely Alzheimers, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, psychiatric diseases and disorders, namely mood disorders, anxiety, cognitive disorders, schizophrenia, cognitive and bipolar disorders, and immune system diseases and disorders, namely autoimmune diseases, and immunologic deficiency syndromes; human vaccines incorporating nano-particles; veterinary vaccines incorporating nano-particles; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and medicines to treat viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders
Custom manufacture of nano-particles; custom manufacture of pharmaceuticals and medicines containing nano-particles; custom manufacture of nano-particle devices; custom manufacture of drug delivery agents for facilitating delivery of pharmaceuticals and medicines; custom manufacture of macrocylic compounds, compositions and derivates used as solubilising and stabilising agents for use in manufacturing pharmaceuticals, medicines and cosmetics
Scientific research services in the field of nano-particle technology; pharmaceutical and drug research, development and discovery services; drug delivery agent research, development and discovery services; testing, efficiency and advisory services in the field of nano-particles, macro-cyclic compounds, pharmaceuticals and nano-medicine; nano-particle laboratory services
What has happened so far
Steps recorded by the CIPO, newest first.
- Registered
- Registration Fee Notice Sent
- Registration Pending
- Advertised; Vol.71 Issue 3637
- Approval Notice Sent; APPROVED BY PROGRAM EX200M1
- Approved; APPROVED BY PROGRAM EX200M1
- Examiner's First Report
- Search Recorded
- Pre-Assessment Letter Sent; Goods or Services Not Acceptable
- Formalized
2 earlier steps on the official record.
About MIDASOLVE
Who owns the trademark "MIDASOLVE"?
The CIPO trademark "MIDASOLVE" (application 1965262) is owned by Midatech Limited.
What is the status of "MIDASOLVE"?
Its status at the CIPO is: registered.
When was "MIDASOLVE" registered?
It was registered on October 9, 2024 and is due to expire on October 9, 2034.
Get this data via the API
Everything on this page comes from the Signa API. Pull MIDASOLVE and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019deb21-5192-70fa-9e89-3eb9dc9d21b7
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019deb21-5192-70fa-9e89-3eb9dc9d21b7",
"object": "trademark",
"mark_text": "MIDASOLVE",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "CA",
"application_number": "1965262",
"filing_date": "2019-05-28",
"nice_classes": [
1,
5,
40,
42
],
"owners": [
{
"name": "Midatech Limited",
"entity_id": "ent_019ebaf3-9aef-735b-a6dd-65e4baf52602"
}
]
}